90Y-OPS201 (90Y-DOTA-JR11, 90Y-SOMTher®) is a proprietary drug that specifically binds to somatostatin receptors (antagonist, ssr2) and can be used for treating neuroendocrine neoplasms. The drug was developed in parallel with the imaging agent 68Ga-OPS202 (SOMScan®). IP apparently covers the product until 2030.
JR11 is a third-generation somatostatin analogue with improved receptor binding to sst2 compared to other currently used peptides. The radiolabeled compound 90Y-OPS201 has the potential to deliver up to five times more dose to NET tumor cells than other radiolabeled somatostatin analogues. On the contrary to all other analogues under development, JR11 is a receptor antagonistic, which provides a different profile to the molecule with some advantages that can be potentially translated into a higher efficacy.
Preclinical development is completed, and the first clinical trial was planned for 2015. However, a higher priority was given to the 177Lu-labeled compound 177Lu-IPN-01072. In the meantime, the alternative to this product on the market is presently 177Lu-Oxodotreotide.
Target/Mechanism: Somatostatine receptors
Leading Emitter: beta electrons (β–)